Bristol-Myers Squibb Competitors

Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and Johnson & Johnson's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Johnson & Johnson's gross revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and Johnson & Johnson, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. Johnson & Johnson has a consensus target price of $178.9333, indicating a potential upside of 14.63%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than Johnson & Johnson.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.6%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 59 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Johnson & Johnson beats Bristol-Myers Squibb on 11 of the 18 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and Eli Lilly and's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Eli Lilly and's gross revenue, earnings per share and valuation.

Eli Lilly and has lower revenue, but higher earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and Eli Lilly and, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. Eli Lilly and has a consensus target price of $192.60, indicating a potential downside of 6.92%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than Eli Lilly and.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.6%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Eli Lilly and beats Bristol-Myers Squibb on 8 of the 15 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and Pfizer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Pfizer's gross revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Bristol-Myers Squibb. Pfizer is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and Pfizer, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. Pfizer has a consensus target price of $39.5333, indicating a potential upside of 14.96%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than Pfizer.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.5%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Pfizer pays out 52.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Summary

Bristol-Myers Squibb beats Pfizer on 11 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.

Earnings and Valuation

This table compares Bristol-Myers Squibb and AbbVie's gross revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Bristol-Myers Squibb. AbbVie is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and AbbVie, as provided by MarketBeat.

Bristol-Myers Squibb currently has a consensus target price of $74.6429, indicating a potential upside of 23.52%. AbbVie has a consensus target price of $115.50, indicating a potential upside of 8.25%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bristol-Myers Squibb is more favorable than AbbVie.

Insider & Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bristol-Myers Squibb and AbbVie's net margins, return on equity and return on assets.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. AbbVie pays out 58.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

AbbVie beats Bristol-Myers Squibb on 12 of the 18 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Earnings and Valuation

This table compares Bristol-Myers Squibb and Merck & Co., Inc.'s revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Bristol-Myers Squibb and Merck & Co., Inc., as provided by MarketBeat.com.

Bristol-Myers Squibb presently has a consensus price target of $74.6429, indicating a potential upside of 23.52%. Merck & Co., Inc. has a consensus price target of $95.3571, indicating a potential upside of 30.39%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Bristol-Myers Squibb.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.6%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Merck & Co., Inc. has increased its dividend for 1 consecutive years.

Profitability

This table compares Bristol-Myers Squibb and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Bristol-Myers Squibb on 13 of the 17 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Zoetis' revenue, earnings per share and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Bristol-Myers Squibb and Zoetis, as reported by MarketBeat.

Bristol-Myers Squibb presently has a consensus price target of $74.6429, suggesting a potential upside of 23.52%. Zoetis has a consensus price target of $167.7273, suggesting a potential upside of 15.13%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, research analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.2%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.7%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Zoetis pays out 27.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 1 consecutive years and Zoetis has raised its dividend for 1 consecutive years.

Profitability

This table compares Bristol-Myers Squibb and Zoetis' net margins, return on equity and return on assets.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

72.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 92.5% of Zoetis shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Zoetis beats Bristol-Myers Squibb on 9 of the 17 factors compared between the two stocks.